• Auxly Cannabis Group (XLY) is expanding into the dried-flower market
  • The company will expand its flower offering under the Kolab Project Growers Series, introduce a strain-specific dried-flower offering and launch pre-roll products under its Kolab Project and Back Forty brands
  • Auxly is an international cannabis company
  • Auxly Cannabis Group (XLY) is up 2.53 per cent, trading at C$0.405 per share at 11am EST

Auxly Cannabis Group (XLY) is expanding into Canada’s largest cannabis segment, the dried-flower market.

Auxly’s three-pronged strategy includes:

  1. Expanding its flower offering under the Kolab Project Growers Series through the launch of new cultivars with existing partners and securing new partnerships with top-tier cultivators
  2. Launching a strain-specific dried-flower offering of unique genetics at a compelling price point under Auxly’s Back Forty brand
  3. Significantly boosting its pre-roll capacity by launching disruptive pre-roll products under its Kolab Project and Back Forty brands.

“We’re proud to have achieved our objective of leading Cannabis 2.0, which remains key to our business strategy,” said Hugo Alves, CEO, Auxly.

“Our 2.0 product offerings under our Kolab Project and Back Forty brands have been a huge hit with consumers, who routinely point to the quality and consistency of our products as the reasons why they choose our brands over others.

We believe that there is a fantastic opportunity to stretch our branded product offering into 1.0 product formats and bring that same quality and consistency that consumers love to our dried-flower and pre-roll products.”

Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets.

Auxly Cannabis Group (XLY) is up 2.53 per cent, trading at C$0.405 per share at 11am EST.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.